{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:46:09Z","timestamp":1792118769750,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["F1-17.1\/2011\/MANF- CHR-KER- 19"],"award-info":[{"award-number":["F1-17.1\/2011\/MANF- CHR-KER- 19"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ejps.2017.03.050","type":"journal-article","created":{"date-parts":[[2017,4,11]],"date-time":"2017-04-11T00:01:22Z","timestamp":1491868882000},"page":"315-325","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects"],"prefix":"10.1016","volume":"104","author":[{"given":"Emil","family":"Joseph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Reddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhu","family":"Rinwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Balwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranendra","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.03.050_bb0005","first-page":"121","article-title":"An animal model of antipsychotic-induced weight gain","volume":"152","author":"Arjona","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejps.2017.03.050_bb0010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.psyneuen.2007.02.005","article-title":"Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion?","volume":"32","author":"Brambilla","year":"2007","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejps.2017.03.050_bb0015","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.addr.2012.09.033","article-title":"Nanoparticle and targeted systems for cancer therapy","volume":"64","author":"Brannon-Peppas","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2017.03.050_bb0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ejps.2017.03.050_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2017.03.050_bb0030","series-title":"Challenges and Opportunities in Schizophrenia Treatment","author":"Cutler","year":"2013"},{"key":"10.1016\/j.ejps.2017.03.050_bb0035","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.colsurfb.2011.07.036","article-title":"Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables","volume":"88","author":"Das","year":"2011","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ejps.2017.03.050_bb0040","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejps.2017.03.050_bb0045","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1166\/jbn.2014.1817","article-title":"Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects","volume":"10","author":"Dimer","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.ejps.2017.03.050_bb0050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s10856-006-8940-4","article-title":"Optimization of preparation of DHAQ-loaded PEG-PLGA-PEG nonaparticles using central composite design","volume":"17","author":"Duan","year":"2006","journal-title":"J. Mater. Sci. Mater. Med."},{"key":"10.1016\/j.ejps.2017.03.050_bb0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ultras.2008.04.009","article-title":"Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells","volume":"49","author":"Fang","year":"2009","journal-title":"Ultrasonics"},{"key":"10.1016\/j.ejps.2017.03.050_bb0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF00433091","article-title":"An observational method for quantifying the behavioural effects of dopamine agonists: contrasting effects of d-amphetamine and apomorphine","volume":"69","author":"Fray","year":"1980","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejps.2017.03.050_bb0065","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpharm.2005.11.040","article-title":"Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles","volume":"310","author":"Gao","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.03.050_bb0070","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.brat.2005.02.007","article-title":"Acute treatment of inpatients with psychotic symptoms using Acceptance and Commitment Therapy: pilot results","volume":"44","author":"Gaudiano","year":"2006","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.ejps.2017.03.050_bb0075","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2165\/00023210-200721110-00004","article-title":"Adverse effects of atypical antipsychotics","volume":"21","author":"Haddad","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejps.2017.03.050_bb0080","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4088\/JCP.v60n0311","article-title":"Suicide victims with schizophrenia in different treatment phases and adequacy of antipsychotic medication","volume":"60","author":"Heila","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejps.2017.03.050_bb0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0169-409X(98)00027-1","article-title":"Pharmacodynamic aspects of sustained release preparations","volume":"33","author":"Hoffman","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2017.03.050_bb0090","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.1986.01800070019003","article-title":"Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia: I One-year effects of a controlled study on relapse and expressed emotion","volume":"43","author":"Hogarty","year":"1986","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejps.2017.03.050_bb0095","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3109\/10717544.2014.926574","article-title":"Surface-coated PLA nanoparticles loaded with temozolomide for improved brain deposition and potential treatment of gliomas: development, characterization and in vivo studies","volume":"23","author":"Jain","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2017.03.050_bb0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0168-3659(99)00223-0","article-title":"Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties","volume":"66","author":"Jenning","year":"2000","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2017.03.050_bb0105","first-page":"1","article-title":"Advances in brain targeted drug delivery: nanoparticulate systems","volume":"3","author":"Joseph","year":"2013","journal-title":"J. PharmaSciTech"},{"key":"10.1016\/j.ejps.2017.03.050_bb0110","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1080\/03639045.2016.1278014","article-title":"Investigations on pharmacokinetics and biodistribution of polymeric and solid lipid nanoparticulate systems of atypical antipsychotic drug: effect of material used and surface modification","volume":"43","author":"Joseph","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2017.03.050_bb0115","first-page":"81","article-title":"Disposition and biotransformation of the antipsychotic agent olanzapine in humans","volume":"25","author":"Kassahun","year":"1997","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2017.03.050_bb0120","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1166\/jnn.2003.077","article-title":"Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain","volume":"4","author":"Kreuter","year":"2004","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.ejps.2017.03.050_bb0125","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.addr.2012.09.015","article-title":"Nanoparticulate systems for brain delivery of drugs","volume":"64","author":"Kreuter","year":"2012","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.ejps.2017.03.050_bb0130","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejps.2017.03.050_bb0135","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2006.08.007","article-title":"Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery","volume":"328","author":"Liu","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.03.050_bb0140","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00004850-200507000-00001","article-title":"Current therapy issues and unmet clinical needs in the treatment of schizophrenia: a review of the new generation antipsychotics","volume":"20","author":"Lublin","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejps.2017.03.050_bb0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jconrel.2005.06.006","article-title":"Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration","volume":"107","author":"Manjunath","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2017.03.050_bb0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2012.09.054","article-title":"Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies","volume":"439","author":"Martins","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.03.050_bb0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijpharm.2012.09.054","article-title":"Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies","volume":"439","author":"Martins","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.03.050_bb0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00213-006-0433-0","article-title":"A model for antipsychotic-induced obesity in the male rat","volume":"187","author":"Minet-Ringuet","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejps.2017.03.050_bb0165","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4314\/tjpr.v5i1.14634","article-title":"Nanoparticles-a review","volume":"5","author":"Mohanraj","year":"2007","journal-title":"Trop. J. Pharm. Res."},{"key":"10.1016\/j.ejps.2017.03.050_bb0170","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.nano.2008.12.003","article-title":"PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation","volume":"5","author":"Muthu","year":"2009","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.ejps.2017.03.050_bb0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0306-4530(02)00114-2","article-title":"A review of the effect of atypical antipsychotics on weight","volume":"28","author":"Nasrallah","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejps.2017.03.050_bb0180","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ejps.2017.03.050_bb0185","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.10.022","article-title":"Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population","volume":"99","author":"Perez-Iglesias","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejps.2017.03.050_bb0190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0091-3057(03)00042-X","article-title":"Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human","volume":"75","author":"Pouzet","year":"2003","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.ejps.2017.03.050_bb0195","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3109\/09687688.2010.510804","article-title":"Nanoparticulate drug delivery systems for cancer chemotherapy","volume":"27","author":"Saha","year":"2010","journal-title":"Mol. Membr. Biol."},{"key":"10.1016\/j.ejps.2017.03.050_bb0200","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1211\/jpp.59.8.0002","article-title":"Solid lipid nanoparticles (SLN) as carriers for the topical delivery of econazole nitrate: in-vitro characterization, ex-vivo and in-vivo studies","volume":"59","author":"Sanna","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2017.03.050_bb0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0939-6411(02)00130-3","article-title":"Solvent injection as a new approach for manufacturing lipid nanoparticles--evaluation of the method and process parameters","volume":"55","author":"Schubert","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2017.03.050_bb0210","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/026520499289185","article-title":"Solid lipid nanoparticles (SLN) for controlled drug delivery II. Drug incorporation and physicochemical characterization","volume":"16","author":"Schwarz","year":"1999","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejps.2017.03.050_bb0215","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10673220600748486","article-title":"Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome","volume":"14","author":"Shirzadi","year":"2006","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.ejps.2017.03.050_bb0220","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.colsurfb.2011.03.035","article-title":"Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound","volume":"86","author":"Silva","year":"2011","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ejps.2017.03.050_bb0225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/10717540802174662","article-title":"Etoposide-loaded PLGA and PCL nanoparticles I: preparation and effect of formulation variables","volume":"15","author":"Snehalatha","year":"2008","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2017.03.050_bb0230","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1016\/j.biomaterials.2003.09.087","article-title":"Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain","volume":"25","author":"Sun","year":"2004","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejps.2017.03.050_bb0235","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/070674379704200304","article-title":"The promise of new drugs for schizophrenia treatment","volume":"42","author":"Tamminga","year":"1997","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.ejps.2017.03.050_bb0240","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ultsonch.2012.04.005","article-title":"Impact of process parameters in the generation of novel aspirin nanoemulsions--comparative studies between ultrasound cavitation and microfluidizer","volume":"20","author":"Tang","year":"2013","journal-title":"Ultrason. Sonochem."},{"key":"10.1016\/j.ejps.2017.03.050_bb0245","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1517\/17425247.2015.1003807","article-title":"Production methods and stabilization strategies for polymer-based nanoparticles and microparticles for parenteral delivery of peptides and proteins","volume":"12","author":"Teekamp","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejps.2017.03.050_bb0250","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.tpj.6500418","article-title":"No evidence for binding of clozapine, olanzapine and\/or haloperidol to selected receptors involved in body weight regulation","volume":"7","author":"Theisen","year":"2007","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.ejps.2017.03.050_bb0255","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/08982100903103904","article-title":"Development and optimization of solid lipid nanoparticles of amikacin by central composite design","volume":"20","author":"Varshosaz","year":"2010","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ejps.2017.03.050_bb0260","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.colsurfb.2010.12.024","article-title":"The size of solid lipid nanoparticles: an interpretation from experimental design","volume":"84","author":"Vitorino","year":"2011","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejps.2017.03.050_bb0265","series-title":"Psychopharmacological Studies in Rodents: Stereotaxic Intracerebral Injections and Behavioural Assessment","author":"Waddington","year":"1986"},{"key":"10.1016\/j.ejps.2017.03.050_bb0270","series-title":"Recovery from Schizophrenia: Psychiatry and Political Economy","author":"Warner","year":"2013"},{"key":"10.1016\/j.ejps.2017.03.050_bb0275","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/jps.10129","article-title":"Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats","volume":"91","author":"Zara","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.03.050_bb0280","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/sj.clpt.6100400","article-title":"Nanoparticles in medicine: therapeutic applications and developments","volume":"83","author":"Zhang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2017.03.050_bb0285","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1124\/jpet.109.160044","article-title":"Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model","volume":"332","author":"Zhou","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717301549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717301549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T18:08:39Z","timestamp":1569002919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717301549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":57,"alternative-id":["S0928098717301549"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.03.050","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.03.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}